EUVIMEDEUVIMED entdecken
Crossref

Dapagliflozin-Induced Cardioprotection in Diabetic Cardiomyopathy Correlates with HMGB1-RAGE Axis Suppression

Ting Zhang, Lizhu Zhang, Yanhua Zeng, Zhe Liao, Zihua Lu, Weini Chen

Indian Journal of Pharmaceutical Education and Research · 23.10.2026 · 61 (1) · 324-330

DOI: 10.5530/ijper.20275430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Pharmaceutical Education and Research, online erschienen am 23.10.2026. Verfasst von Ting Zhang und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetic Cardiomyopathy (DCM) is a clinically important cardiac complication of Type 2 Diabetes Mellitus (T2DM). Its progression is closely related not only to chronic hyperglycemia and metabolic overload, but also to sustained inflammatory activation. Among the candidate inflammatory pathways, the High Mobility Group Box 1 Protein (HMGB1)-Receptor for Advanced Glycation End products (RAGE) axis has attracted attention because it can connect tissue injury, innate immune signaling, and adverse myocardial remodeling.

Objectives

To examine whether dapagliflozin can improve myocardial function in patients with T2DM complicated by DCM and to explore whether the benefits are associated with downregulation of circulating HMGB1 and RAGE. Materials and Methods: Eighty patients with T2DM-associated DCM who were admitted to the Department of Endocrinology of Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine between July 2023 and July 2024 were randomly assigned to a control group or an observation group, with 40 cases in each arm. All participants received conventional management. The control group was treated with metformin sustained-release tablets, whereas the observation group received dapagliflozin in addition to metformin. The intervention period was 6 months. Fasting Blood Glucose (FBG), 2-hr Postprandial Blood Glucose (2hPBG), Glycated Hemoglobin (HbA1C), serum HMGB1, serum RAGE, and the myocardial performance index (Tei index) were assessed before treatment and again at 3 and 6 months.

Results

Baseline characteristics were comparable between the two groups. After treatment, both regimens were associated with lower FBG, 2hPBG, HbA1C, HMGB1, RAGE, and Tei index compared with pretreatment levels. However, the decreases in glycemic variables and inflammatory markers were greater in the dapagliflozin group than in the metformin-alone group at both follow-up points (all p

Zitieren

APA

Zhang, T., Zhang, L., Zeng, Y., Liao, Z., Lu, Z., & Chen, W. (2026). Dapagliflozin-Induced Cardioprotection in Diabetic Cardiomyopathy Correlates with HMGB1-RAGE Axis Suppression. Indian Journal of Pharmaceutical Education and Research, 61(1), 324-330. https://doi.org/10.5530/ijper.20275430

Vancouver

Zhang T, Zhang L, Zeng Y, Liao Z, Lu Z, Chen W. Dapagliflozin-Induced Cardioprotection in Diabetic Cardiomyopathy Correlates with HMGB1-RAGE Axis Suppression. Indian Journal of Pharmaceutical Education and Research. 2026;61(1):324-330. doi:10.5530/ijper.20275430

BibTeX
@article{Zhang2026,
  author = {Zhang, Ting and Zhang, Lizhu and Zeng, Yanhua and Liao, Zhe and Lu, Zihua and Chen, Weini},
  title = {Dapagliflozin-Induced Cardioprotection in Diabetic Cardiomyopathy Correlates with HMGB1-RAGE Axis Suppression},
  journal = {Indian Journal of Pharmaceutical Education and Research},
  year = {2026},
  volume = {61},
  number = {1},
  pages = {324--330},
  doi = {10.5530/ijper.20275430}
}
Kostenlos starten →